Notable Downgrades: Baidu (BIDU), TripAdvisor (TRIP), PTC Therapeutics (PTCT), InvenSense (INVN), Keryx Biopharmaceuticals (KERX)

Analysts at JP Morgan (JPM) downgraded Baidu, Inc. (BIDU) from ‘Overweight‘ to ‘Neutral‘ in a research report issued to clients on Tuesday.

The target price for BIDU is lowered from $240 to $215.

On valuation measures, Baidu Inc. ADS stock it’s trading at a forward P/E multiple of 3.29x, and at a multiple of 32.23x this year’s estimated earnings. The t-12-month revenue at Baidu is $7.91 billion. BIDU ‘s ROE for the same period is 25.73%.

Shares of the $68.11 billion market cap company are up 27.38% year-over-year ; down 10.65% year-to-date.

Baidu Inc, currently with a median Wall Street price target of $250.00 and a high target of $280.00, dropped $9.70 to $194.00 in recent trading.

The chart below shows where the equity has traded over the past 52-weeks.

TripAdvisor Inc. (TRIP) was downgraded from ‘Outperform‘ to ‘Sector Perform‘ and the price target was set at $91 at RBC Capital Markets.

Shares have traded today between $77.33 and $79.82 with the price of the stock fluctuating between $66.04 to $111.24 over the last 52 weeks.

TripAdvisor Inc. shares are currently changing hands at 49.92x this year’s forecasted earnings, compared to the industry’s 18.09x earnings multiple. Ticker has a t-12 price/sales ratio of 9.17. EPS for the same period registers at $1.55.

Shares of TRIP have lost $2.54 to $77.37 in mid-day trading on Tuesday, giving it a market cap of roughly $11.06 billion. The stock traded as high as $111.24 in June 30, 2014.

ROTH Capital reported on Tuesday that they have lowered their rating for PTC Therapeutics, Inc. (PTCT). The firm has downgraded PTCT from ‘Buy‘ to ‘Neutral‘ and lowered its price target to $63 from $75.

PTC Therapeutics Inc. recently traded at $54.43, a loss of $6.41 over Monday’s closing price. The name has a current market capitalization of $1.83 billion.

InvenSense, Inc. (INVN) had its rating lowered from ‘Buy‘ to ‘Hold‘ by analysts at Craig Hallum on Tuesday. The firm sees shares as fairly valued at $15, versus $15.53 close. Currently there are 8 analysts that rate INVN a ‘Buy‘, no analysts rate it a ‘Sell‘, and 7 rate it a ‘Hold‘.

INVN was down $0.29 at $15.24 in mid-day trade, moving within a 52-week range of $13.19 to $26.78. The name, valued at $1.38 billion, opened at $14.54.

On valuation measures, InvenSense Inc. shares have a t-12 price/sales ratio of 4.23. EPS for the same period registers at ($0.08).

Shares of Keryx Biopharmaceuticals Inc. (KERX) are down $0.24 at $10.24, after Maxim Group this morning lowered its price target on the shares to $17 from $32, and reiterated a ‘Buy’ rating.

KERX shares recently lost 2.19%. The stock is down 27.72% year-over-year and has lost roughly 26% year-to-date. In the past 52 weeks, shares of the Charlotte, North Carolina-based company have traded between a low of $9.80 and a high of $18.48.

Keryx Biopharmaceuticals Inc. closed Monday at $10.48. The name has a current market cap of $1.06 billion.

Be the first to comment

Leave a Reply

Your email address will not be published.


*